To the Editor:
Acid-suppressive medications, such as H2-receptor antagonists (H2RA) and proton pump inhibitors (PPI), are the main treatment options for dyspepsia and gastroesophageal reflux disease. These are common problems in pregnancy. 1 Recently, concerns have been raised that prenatal exposure to these medications may increase the risk of allergic disease in the offspring, which was first reported by Sch€ oll and colleagues. 1 This was followed by the study by Dehlink and colleagues 2 who reported the first findings in humans, proposing that use of acid-suppressive medications in pregnancy may increase the risk of allergic disease in the offspring through interference with maternal digestion of labile antigens, thereby increasing the amount of allergen to which the fetus is exposed. PPI use has also been linked to changes in the intestinal microbiota composition, 3 which may also increase the risk of T H 2-mediated conditions, such as asthma and allergy. Supporting the findings from the study by Sch€ oll and colleagues, 1 Dehlink et al 2 therefore proposed that acidsuppressive medications could operate through 1 or both of these mechanisms, inducing a T H 2 cytokine pattern in mothers that could then cross the fetal membrane and induce sensitization of fetal immune cells to food and airborne allergens prior to birth.
An increasing number of studies have now investigated the impact of prenatal exposure to acid-suppressive medications on the risk of allergic disease in the offspring but with inconsistent results. 2, [4] [5] [6] [7] [8] [9] [10] To obtain a clearer appreciation of the evidence base, we undertook a systematic review and meta-analysis of these studies. We were also interested in clarifying whether use of the subtypes of acid-suppressive medications, namely H2RA and PPIs, was associated with asthma/allergy and whether any associations uncovered varied by time (trimester), dose, and frequency of exposure.
We included analytical epidemiological studies (ie, cohort, case-control, and cross-sectional studies). We excluded reviews, case studies and case series, and animal studies. All women during preconception and pregnancy and their offspring who were < _17 years were eligible for inclusion. Our primary outcomes were (1) objectively defined asthma, atopic dermatitis/eczema, allergic rhinitis or hay fever, food allergy, urticaria, and anaphylaxis and (2) atopic sensitization as defined either by skin prick test or raised antigen-specific IgE (see description of secondary outcomes in Study outcomes of this article's Online Repository at www.jacionline.org).
To identify relevant studies, we searched 11 electronic databases and searched databases of ongoing studies and conference abstracts (see details in the Information sources, search strategy, and study selection section of this article's Online Repository). We also contacted experts in the field to identify additional studies and any ongoing studies. We developed a detailed search strategy in MEDLINE, which was then adapted for searching other databases (Table E1 in this article's Online Repository at www.jacionline.org). All databases were searched from inception to the end of 2015, with no language restrictions. Two reviewers (R.E.D. and B.I.N.) independently screened all titles and/or abstracts, screened full texts of potentially eligible studies, extracted study data onto a customized data extraction form, and quality appraised all studies using the Effective Public Health Practice Project tool (Hamilton, Ontario, Canada) . Any discrepancies in the process were resolved by discussion or a third reviewer (N.M.) arbitrated. We graded key components from which we derived an overall grading for each study as strong, moderate, or weak (see Tables E2 and E3 in this article's Online Repository at www.jacionline.org).
We employed random-effects meta-analysis to quantify the pooled effect estimates for reasonably homogeneous studies. Metaanalysis was possible with studies on risk of asthma but not for other outcomes due to insufficient number of studies. Dosage, trimester, and frequency of exposure to acid-suppressive medications were differentially reported across studies; hence we were unable to pool studies on these exposures. We quantified the level of heterogeneity between studies using the I 2 statistic (values near 0 indicate good homogeneity across studies). Meta-analyses were undertaken using Stata 14 (StataCorp LP, College Station, Tex) . See this article's Online Repository (www.jacionline.org) for a fuller description of our approach to data synthesis and application of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Of the 3282 records identified from our searches, 8 studies (Figs 1 and 2) . Results of sensitivity analyses are given in this article's Online Repository. Two studies that considered other allergic disorders both reported an increased risk among offspring of mothers using any acid-suppressive medications, H2RA, and PPIs compared with the offspring of nonusing mothers 2, 8 (see Table E2 in this article's Online Repository). By applying the GRADE approach, we graded the evidence regarding the risk of asthma as moderate, but evidence regarding other allergic outcomes as very low (see Table E4 in this article's Online Repository at www.jacionline.org). The Egger test (to evaluate publication bias and small-study effect) for the association between use of any acid-suppressive medications and risk of asthma showed P 5 .415.
Our literature search was comprehensive. We had no language restriction, used reproducible search strategies, and applied rigorous review processes, which were enhanced by publishing and registering a detailed protocol prior to undertaking the review. 11 The degree of heterogeneity among studies was low; the only case of high heterogeneity was due to differences in the definition of the exposure. In the course of our literature search, we found a recent systematic review from Google Scholar, published in Chinese in a local journal. 12 Five studies were included in that review and were meta-analyzed. On translation to English, we found that the systematic review process was deficient in many aspects, including the following: lack of information about quality assessment, data extraction, or the number of reviewers involved; unclear decisions regarding meta-analysis decisions (whether fixed-effect or random-effects meta-analysis was used) or the approach employed to evaluate heterogeneity between studies. Animal models and studies undertaken in adults suggest that acid-suppressive medications may interfere with peptide digestion, thereby inducing a T H 2 cytokine dominance, which may result in subsequent sensitization of the immune system. 2 Such interference may increase the amount of allergen the fetus is exposed to via the placenta, thereby resulting in sensitization and subsequent development of allergic disorders and asthma. 2 Our findings of increased risk may reflect a true risk or may be explained by residual confounding and/or confounding by indication. Of note is that none of the studies adjusted for the full panel of known confounders in these associations. Although we cannot recommend any changes to the use of acid-suppressive medications by expectant mothers, further research is needed, particularly through mounting pharmacovigilance studies, which may prove more ethically acceptable and feasible than initiating randomized controlled clinical trials.
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Improvement of idiopathic membranous nephropathy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor
To the Editor:
The diagnosis of glomerulonephritis is generally based on kidney biopsy, which few diagnostic serologic markers have been described. M-type phospholipase A2 receptor (PLA2R) is a type I transmembrane protein abundantly expressed on glomerular podocytes. Antibodies against PLA2R were described by Beck et al 1 as serum markers for idiopathic membranous nephritis (IMN). Recently, anti-PLA2R antibodies were found to correlate with disease activity and proteinuria in IMN.
2 Anti-PLA2R antibody levels decreased or disappeared on treatment induction or spontaneous remission in patients with IMN. In serial investigations, anti-PLA2R antibodies were found in 70% of IMN and a small percentage (5% to 25%) were positive in sera from patients with secondary MN by qualitative analysis, such as Western immnunoblot, indirect immunofluorescence cell based assay (IIF-CBA), and ELISA, [3] [4] [5] which negatively affected the differential diagnosis of IMN. A quantitative assay is needed to distinguish IMN from secondary MN.
Taking advantage of the highly sensitive time-resolved fluoroimmunoassay (TRFIA) format, we developed a quantitative method for detection of anti-PLA2R antibody in serum and used it in the evaluation of renal patients. In this study, recombinant PLA2R was generated by cloning into 293T cells. Serum samples from 286 healthy volunteers without evidence of nephropathy, gastroduodenal disorder, or liver diseases were
METHODS

Ethics approval
We completed the University of Edinburgh's Usher Institute of Informatics and Population Health Sciences Level 1 Ethics Clearance, which revealed that no further ethics clearance is required because the study is based on published literature.
Protocol and registration
Prior to commencement of the review, we developed a detailed protocol, which was published E1 and registered with the International Prospective Register of Systematic Reviews (PROSPERO; www.crd.york.ac.uk/ prospero/, reference CRD42015029584).
Eligibility criteria
We included analytical epidemiological studies: cohort, case-control, and cross-sectional studies. We excluded reviews, case studies and case series, and animal studies. All women during preconception and pregnancy and their offspring who were < _17 years were eligible for inclusion.
Types of exposure
We considered all studies that investigated the association between maternal use of any type of acid-suppressive medications ([ASMs], ie, H2-receptor antagonists [H2RA], proton pump inhibitors [PPIs] , and antacids) during pregnancy and the risk of asthma and allergy in the offspring. We also considered the dose, frequency, and timing (trimester) of use of these medications.
Study outcomes
Our primary outcomes were objectively defined asthma, atopic dermatitis/ eczema, allergic rhinitis or hay fever, anaphylaxis, food allergy, urticaria, and anaphylaxis by physician or hospital record or self-reported. Atopic sensitization as defined either by skin prick test or raised antigen-specific IgE. Secondary outcomes included objective and subjective measures of disease severity and impact on quality of life, including asthma exacerbations, use of asthma medications, hospitalization for asthma, wheeze as defined by self-report or objective diagnosis; indicators of airway function including (peak expiratory flow, forced expiratory volume in 1 second, forced vital capacity, forced expiratory flow rate or alternative age appropriate pulmonary function tests [oscillometry or exhaled nitric oxide analysis]); and measures of health-related quality of life.
Information sources, search strategy, and study selection
We searched the following international electronic databases: MEDLINE, EMBASE, Web of Science CORE, BIOSIS, CINAHL, Cochrane Library, Global Health CABI, Global Health Library, Scopus, Popline, and Google Scholar. Additional studies were retrieved by manual search of the references of eligible papers and by contacting a panel of international experts on the topic. Conference abstracts were retrieved by searching ISI Conference Proceedings Citation Index via Web of Knowledge and ZETOC (British Library). Unpublished and in-progress studies were identified by searching Current Controlled Trials, ClinicalTrials.gov, Australian and New Zealand Clinical Trials Registry. We developed a detailed search strategy in MEDLINE, which was then adapted in searching other databases (Table E1 ). All databases were searched from inception to the end of 2015, with no language restrictions. Identified records were exported to Endnote Library for screening. After removal of duplicate records, 2 reviewers (R.E.D. and B.I.N.) independently screened all titles and/or abstracts. Full texts of potentially eligible studies were obtained and independently screened for inclusion by the 2 reviewers. Studies that did not fulfill the inclusion criteria were excluded. Any discrepancies in the screening process were resolved by discussion.
Data extraction and quality assessment
Two reviewers (R.E.D. and B.I.N.) independently extracted study data onto a customized data extraction form. The data extraction form was piloted and revised prior to use in collecting data from all studies. Discrepancies in data extraction were resolved by discussion and arbitration by a third reviewer (N.M.). The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) checklist guided reporting.
E2
Risk of bias in individual studies
Two reviewers (R.E.D. and B.I.N.) independently undertook the risk of bias analysis in the study using the Effective Public Health Practice Project tool (Hamilton, Ontario, Canada), which was adapted for use in this review. We graded key components of each study as strong, moderate, or weak: suitability of the study design for the research question, validity of exposure and outcome assessments, potential for selection bias, and appropriate adjustment for confounding factors. From these component-specific assessments, we derived an overall grading for each study as strong, moderate, or weak. Any discrepancies were resolved by discussion or a third reviewer (N.M.) arbitrated. were converted to RR using the formulae by Grant E11 and then pooled with the Yitshak-Sade et al E6 study. The formula for conversion is given as follows:
Summary measures
, where p0 is the baseline risk. The baseline risks for Dehlink et al E7 and K€ all en et al E8 were taken from the respective papers. The baseline risk for E9 was taken from Mulder et al (2014), E4 which was based on the same study population. For Hak et al, E10 we used the prevalence estimate (4.2%) reported elsewhere but based on a similar primary care database. E12 The RR derived from these calculations are presented in Table E5 .
Data synthesis
Of the 8 studies, 6 were retrospective cohort studies, E3-E8 and 2 were casecontrol studies. E9,E10,E13,E14 We summarized the overall evidence both narratively and quantitatively. For the quantitative synthesis, we employed randomeffects meta-analysis to quantify the pooled effect estimates for sufficiently clinically, methodologically, and statistically homogeneous studies. E9 analyzed 2 sets of control populations that were compared with the same asthma cases: sibling-based controls and non-sibling-based controls. In the analysis, we treated these sets of case-control populations independently. This was applicable for use of any ASMs, H2RA only, and PPIs only; there were no data on use of antacids. Dosage of ASMs and trimester of exposure were differentially reported across studies; hence we were unable to pool studies on these exposures. Meta-analysis was possible only with studies on asthma and not for other outcomes as an insufficient number of studies were available for other allergic outcomes. In the meta-analysis, studies reporting HR and RR were separately pooled. We quantified the level of heterogeneity between studies using the I 2 statistic. In addition to the overall summary effect estimate, we also estimated the 95% prediction interval, which takes into account the overall uncertainty surrounding the summary effect and heterogeneity across studies to provide a range for which we are 95% confident that the effect of ASMs on the risk of asthma in new studies would lie. E13 Given that the number of studies for each meta-analysis was small, thus lacking the required power (ie, less than the recommended minimum of 10 studies), E14 we were unable to graph the funnel plots to evaluate possible publication bias or small study effect; hence we performed the Begg and Egger tests for this purpose. E15 Meta-analyses were undertaken using Stata statistical software (release 14; StataCorp LP, College Station, Tex).
Sensitivity analyses
Given observed high heterogeneity across studies in the meta-analysis of the association between use of any ASMs or H2RA/PPIs, we undertook the following steps to explore possible reasons for the heterogeneity. First, we stratified the analysis by study design (cohort vs case-control studies). Second, given that within the cohort studies, in comparison to other studies, the study by Yitshak-Sade et al (2015) studied use of H2RA or PPIs rather than use of any ASMs, we excluded that study to assess its impact on the heterogeneity across studies.
Grading the quality of the overall body of evidence
Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, we first identified all potentially relevant outcomes and rated their relative clinical importance: asthma was considered a critical outcome; atopic dermatitis/eczema, allergic rhinitis, and other allergic disorders were considered as important outcomes. Second, we appraised the quality of the overall evidence for each outcome and presented this information using the GRADE evidence profiling table template. E16 
RESULTS
Study selection
We identified 3282 records, of which 3057 were included for screening by title and/or abstract after deduplication. Of these, 3033 were excluded for not meeting the inclusion criteria, leaving 24 papers for full text screening. A further 16 papers were excluded, leaving 8 papers that met our inclusion criteria (Fig E1) .
E3-E10
Study characteristics
All studies were either based on a primary care database or population-based prescription or dispensing database. Two studies each were undertaken in The Netherlands, E4,E9 Sweden, E7,E8 and United Kingdom, E5,E10 whereas 1 study each was undertaken in Denmark E3 and Israel. E6 All studies considered asthma as an outcome and 2 additionally considered other allergic disorders, including atopic dermatitis/eczema and allergic rhinitis. E4,E7 Whereas most studies considered use of any ASMs or H2RA/ PPIs, E4,E7-E10 the independent role of H2RA and PPIs were examined in 3 studies, E3,E4,E6 but no study examined the role of antacids alone. Seven of the studies also considered the trimester of exposure to ASMs, and 3 examined the dosage of use, commonly defined as defined daily doses; however, marginally different definitions of trimester and dosage were used across studies.
Risk of bias within studies
Based on overall risk of bias assessment in the studies, 6 studies were graded as strong and 2 as moderate. The overall quality grading was derived from the grading for the different components of the studies. Apart from Mulder et al, E9 which was graded weak for confounding adjustment, all other studies were graded moderate or strong for all components (Table E3) .
Use of ASMs and risk of asthma
Across individual studies, offspring of mothers who used any ASMs during pregnancy were at an increased risk of asthma compared with offspring of nonusers ( Table E2) . The results were similar when H2RA and PPIs were examined separately, except for imprecise estimates from 2 studies. E4,E5 Higher dosage of ASMs appeared to show a greater risk compared with lower dosage (Table E2 ). Whereas use of ASMs during any trimester of pregnancy was associated with an increased risk of asthma, there was no clear indication that any specific trimester was associated with greatest risk (Table E2 ). The high heterogeneity in the analysis of the use of any ASMs was reduced in further exploration, as explained in the sensitivity analysis section.
Use of ASMs and risk of other allergic disorders
The association between use of ASMs and other allergic disorders was investigated by 2 studies, E4,E7 both reporting an increased risk among offspring of mothers using any ASMs, H2RA, and PPIs, compared with those of nonusing mothers (Table E2) . Mulder et al, E4 in addition, reported an increased risk of atopic dermatitis/eczema and allergic rhinitis with use of ASMs, although estimates were imprecise in some cases for the independent roles of H2RA and PPIs (data not shown). Given the different effect measures used by Dehlink et al E7 (OR) and Mulder et al E4 (HR) , and considering that only Mulder et al (2014) E4 examined atopic dermatitis/eczema and allergic rhinitis, we could not calculate pooled estimates of the association between ASMs and risk of allergic disorders other than asthma.
Sensitivity analyses
By stratifying the association between use of any ASMs or H2RA/PPIs by study design, the results showed that the high heterogeneity was specific to the cohort studies (Fig 1) . Further exclusion of the study by Yitshak-Sade et al E6 reduced the heterogeneity in all studies from the initial 87% to 18% and the heterogeneity in the cohort studies from 95% to 0% (Fig 1) . Stratification of the results by study design and exclusion of the Yitshak-Sade et al E6 study did not dramatically change the pooled relative effect estimates, but did result in a more precise predictive interval (1.23-1.75) (Fig 1) .
Grading quality of the overall body of evidence
By applying the GRADE system (Table E4) , we graded the evidence regarding risk of asthma as moderate. None of the studies assessed the possible influence of confounding by indication or unmeasured confounding, and ASMs data were based on either prescribed or dispensed medication without information on actual use. It is therefore possible that the results could be partly explained by these factors. Given very few studies, we graded the evidence regarding atopic dermatitis/eczema, allergic rhinitis, and other allergic outcomes as very low.
Assessment of publication bias
We calculated the Egger test for the association between use of any ASMs and risk of asthma, and the result showed P 5 .415 (Table E5 ), indicating that publication bias or small study effect was unlikely to have influenced our results. The overall risk assessment was based on the component risk assessments (ie, on the suitability of the study design for the research question, validity of exposure and outcome assessments, potential for selection bias, adjustment for confounding factors). ASM, Acid-suppressive medication. ASM, Acid-suppressive medications; GRADE, Grading of Recommendations Assessment, Development and Evaluation; H2RA, H2-receptor antagonists; HR, hazard ratio; PPI, proton pump inhibitor; RR, risk ratio. *All studies were registry-based studies derived from population-based health care registers or general practitioner database. Overall, estimates of the test of heterogeneity across studies was low. The initial observed high heterogeneity in the pooled estimates was explained by pooling together studies on any ASM and H2RA/PPI, but the heterogeneity was removed after excluding studies on H2RA/PPI from the pooled data. àIt is unlikely that we had missed any eligible study for inclusion: with highly sensitive search strategies, we searched 11 leading medical electronic databases, contacted experts in the field, and searched abstract and ongoing studies databases for additional references. Egger test for small-study effect for the pooled estimate was statistically nonsignificant. §It is plausible that confounding by indication, residual confounding, or other unmeasured confounding factors could have influenced these observations. Data on use of ASM across studies were based on either prescription or dispensed medication; hence actual use was not ascertained. Given some inconsistency in reporting dosage and trimester of exposure to ASM, dose-response gradients of effect could not be evaluated in a pooled analysis. jjOnly 1 study evaluated this outcome; hence consistency across studies and precision of the pooled overall estimated could not be evaluated. {Each study calculated the risk estimate using different measures (hazard or odds ratios), which did not allow pooling of the studies. #Although pooled estimates could not be calculated from the studies because of different measures used to estimate risk effects across studies, the estimates provided in each study were precise. ASM, Acid-suppressive medications; OR, odds ratio; RR, risk ratio. *Guddat et al E13 (2012) . The same formula was used for converting the lower and upper 95% CIs as suggested by Robert Grant in an electronic correspondence.
Mulder et al E9 (2013) undertook 2 sets of analysis using the same asthma cases but different controls in the same study and compared estimates from analyses: in 2013a, they used siblings of the cases as the controls, and in 2013b, they used nonsiblings as controls. Hence each analysis was regarded as independent on its own right given the different control populations.
